Research Reports
Osteoporosis Drugs Market is Presumed to be Valued at US$ 11.7 Bn by 2027
Published by TMR Research Insights
Posted on August 27, 2021
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by TMR Research Insights
Posted on August 27, 2021
According to Transparency Market Research’s latest report on the global osteoporosis drugs market for the historical period 2017–2018 and forecast period 2019–2027, rising prevalence of osteoporosis, growing aging population which is more prone to osteoporosis, and introduction of new therapies are projected to drive the global Osteoporosis Drugs market during the forecast period. According to the report, the global osteoporosis drugs market was valued at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2027.
Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone fragility and threat of bone cracks and fractures. Thus, osteoporosis is considered life threatening due to severe injury and associated pain. Elevation in threat of bone cracks and introduction of new drug therapy classes are the factors that are fuelling the growth of osteoporosis drugs market. Since there is no distinct substitute available to treat osteoporosis (such as, surgery), the drugs therapy is an inevitable part of osteoporosis treatment. Growing aging population leads for higher prevalence of osteoporosis which brings more growth opportunities for osteoporosis drugs market.
Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=133
Growing Prevalence of Osteoporosis Across Globe is Key Market Driver
Higher incidence & prevalence of osteoporosis across the world is the major driver for the growth of global osteoporosis market. For instance, according to International Osteoporosis Foundation, Osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds and also it is estimated to affect 200 million women globally.
Moreover growing aging population aged above 50 years are at the greatest risk of developing osteoporosis and related fractures due to hormonal changes. So this rise in aging population also fuelling the growth of global market. Development of novel approaches for the treatment of osteoporosis by new drugs and increase in awareness among people for the early diagnosis & treatment are also some of the major factors for the growth of this market.
Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=133
Patent expiry and loss of exclusivity are considered major restraints of the osteoporosis drugs market. As the generic equivalents of branded drugs are manufactured and marketed at 1/10th of the price of the original branded drug, loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to almost 35% – 40% in the first year.
This low cost of generics results in higher consumption, although, generic drugs are not able to achieve or exceed the overall sales of the branded formulation. On the basis of region, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
North America to Continue Providing Lucrative Growth Opportunities Over Forecast Period
North America region dominated the global market owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose. However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.
Buy Osteoporosis Drugs Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=133<ype=S
The global osteoporosis drugs market is highly fragmented, with the presence of a number of international as well as regional players. Leading players operating in the global Osteoporosis Drugs market are Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Merck & Co., Inc., Radius Health, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., UCB S.A., Mylan N.V., and Apotex Inc.
More Trending Reports by Transparency Market Research –
Macular Degeneration Treatment Market: https://www.prnewswire.com/news-releases/novel-therapies-in-macular-degeneration-treatment-market-to-decrease-progression-to-help-reduce-vision-loss-global-valuation-to-touch-mark-of-us-11-1-bn-by-2026-tmr-301300915.html
Surgical Drills Market: https://www.prnewswire.com/news-releases/prevalence-of-chronic-diseases-that-need-surgical-processes-spurs-sales-in-surgical-drills-market-valuation-to-rise-at-cagr-of-4-7-during-20182026-tmr-301265120.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Transparency Market Research
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Blog: https://tmrblog.com/
Follow Us: Twitter | LinkedIn
Press Release Source: https://www.transparencymarketresearch.com/pressrelease/osteoporosis-drug-market.htm
According to Transparency Market Research’s latest report on the global osteoporosis drugs market for the historical period 2017–2018 and forecast period 2019–2027, rising prevalence of osteoporosis, growing aging population which is more prone to osteoporosis, and introduction of new therapies are projected to drive the global Osteoporosis Drugs market during the forecast period. According to the report, the global osteoporosis drugs market was valued at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2027.
Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone fragility and threat of bone cracks and fractures. Thus, osteoporosis is considered life threatening due to severe injury and associated pain. Elevation in threat of bone cracks and introduction of new drug therapy classes are the factors that are fuelling the growth of osteoporosis drugs market. Since there is no distinct substitute available to treat osteoporosis (such as, surgery), the drugs therapy is an inevitable part of osteoporosis treatment. Growing aging population leads for higher prevalence of osteoporosis which brings more growth opportunities for osteoporosis drugs market.
Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=133
Growing Prevalence of Osteoporosis Across Globe is Key Market Driver
Higher incidence & prevalence of osteoporosis across the world is the major driver for the growth of global osteoporosis market. For instance, according to International Osteoporosis Foundation, Osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds and also it is estimated to affect 200 million women globally.
Moreover growing aging population aged above 50 years are at the greatest risk of developing osteoporosis and related fractures due to hormonal changes. So this rise in aging population also fuelling the growth of global market. Development of novel approaches for the treatment of osteoporosis by new drugs and increase in awareness among people for the early diagnosis & treatment are also some of the major factors for the growth of this market.
Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=133
Patent expiry and loss of exclusivity are considered major restraints of the osteoporosis drugs market. As the generic equivalents of branded drugs are manufactured and marketed at 1/10th of the price of the original branded drug, loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to almost 35% – 40% in the first year.
This low cost of generics results in higher consumption, although, generic drugs are not able to achieve or exceed the overall sales of the branded formulation. On the basis of region, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
North America to Continue Providing Lucrative Growth Opportunities Over Forecast Period
North America region dominated the global market owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose. However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.
Buy Osteoporosis Drugs Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=133<ype=S
The global osteoporosis drugs market is highly fragmented, with the presence of a number of international as well as regional players. Leading players operating in the global Osteoporosis Drugs market are Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Merck & Co., Inc., Radius Health, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., UCB S.A., Mylan N.V., and Apotex Inc.
More Trending Reports by Transparency Market Research –
Macular Degeneration Treatment Market: https://www.prnewswire.com/news-releases/novel-therapies-in-macular-degeneration-treatment-market-to-decrease-progression-to-help-reduce-vision-loss-global-valuation-to-touch-mark-of-us-11-1-bn-by-2026-tmr-301300915.html
Surgical Drills Market: https://www.prnewswire.com/news-releases/prevalence-of-chronic-diseases-that-need-surgical-processes-spurs-sales-in-surgical-drills-market-valuation-to-rise-at-cagr-of-4-7-during-20182026-tmr-301265120.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Transparency Market Research
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Blog: https://tmrblog.com/
Follow Us: Twitter | LinkedIn
Press Release Source: https://www.transparencymarketresearch.com/pressrelease/osteoporosis-drug-market.htm